Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer
20 January 2021 07:00 GMT Enhertu approved in the EU for the treatmentof HER2-positive metastatic breast cancer Approval based on DESTINY-Breast01 Phase II trial which showed clinically meaningful and durable responses in patients with previously treated disease AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-